✦ LIBER ✦

Biweekly docetaxel (DOC), gemcitabine (GEM), oxaliplatin (LOHP) in heavily pretreated patients with solid tumors — Preliminary results of a phase I study

✍ Scribed by Büchele, T.; Grothey, A.; Voigt, W.; Kegel, T.; Rie, C.; Wunderlich, D.; Schmoll, H.J.

Book ID: 123567224
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 135 KB
Volume: 35
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(99)81576-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of gemcitabine and docet

A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors

✍ David P. Ryan; Thomas J. Lynch; Michael L. Grossbard; Michael V. Seiden; Charles 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 2 views

A Phase I study was initiated to determine the maximum tolerated dose of weekly gemcitabine combined with monthly, fixed-dose docetaxel. ## METHODS. Patients with metastatic solid tumors were treated with docetaxel, 60 mg/m 2 , on Day 1 every 28 days. Gemcitabine was administered on Days 1, 8, and

Feasibility of biweekly combination chem

Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX

✍ T. Mazard; M. Ychou; S. Thezenas; S. Poujol; F. Pinguet; A. Thirion; J. P. Bleus 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 197 KB

Phase I and pharmacoklnetic (PK) study o

Phase I and pharmacoklnetic (PK) study of irinotecan (CPT-11) and cisplatin in patients with solid tumors: Preliminary results

✍ de Jonge, M.J.A.; Spareboom, A.; Planting, A.S.Th.; van der Burg, M.E.L; de Brui 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 255 KB

1468 POSTER A phase 1B, open-label, dose

1468 POSTER A phase 1B, open-label, dose-escalation study of bortezomib (Btz) in combination with gemcitabine (G) and cisplatin (C) in the first-line treatment of patients with advanced solid tumors: preliminary results

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 148 KB

282 POSTER Preliminary results of a Phas

282 POSTER Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors

✍ P. Schöffski; H. Dumez; S.F. Jones; C. Fowst; P. Gerletti; H. Xu; J. Jakubczak; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 64 KB

346 POSTER CBP501, a novel cell cycle G2

346 POSTER CBP501, a novel cell cycle G2 checkpoint abrogator. Preliminary results of the initial phase I and pharmacokinetic (PK)/pharmacodynamic (PD) study in patients (pts) with advanced solid tumors

✍ M.S. Gordon; J.P. Eder; D.S. Mendelson; E. Wasserman; W. Sutherland; T. Kawabe; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 58 KB